Duration of clinical response

Quality of Life Claims: Impact on symptoms, functioning, or PROs

Claims that are not supported by adequate Phase 3 evidence may be rejected or require additional trials.

Regulatory Expectations for Claim Justification

Both the FDA and EMA expect that label claims are:

• Supported by pre-specified primary or key secondary endpoints
• Statistically significant within controlled clinical trials
• Clinically meaningful as evaluated by medical reviewers
• Consistent across relevant subgroups and sensitivity analyses

Ad-hoc analyses or exploratory endpoints are generally not acceptable for pivotal claims but may inform descriptive labeling.

Step-by-Step Process for Claim Justification Using Phase 3 Data

1. Identify Target Claims During Trial Design

Work with clinical, regulatory, and commercial teams to define which claims are strategically important. Then:

• Include those claims in your target product profile (TPP)
• Design primary and key secondary endpoints around them
• Power the study adequately to detect meaningful differences

Early alignment ensures the protocol supports future labeling goals.

2. Use the Right Endpoints

• Claims about efficacy must be supported by primary or key secondary endpoints
• PRO-related claims require validated instruments and clinically meaningful cutoffs
• Comparative claims demand a head-to-head trial with appropriate statistical models

Claims based on surrogate or biomarker endpoints may be considered if supported by prior validation and regulatory acceptance.

3. Ensure Statistical and Clinical Significance

Regulators expect both:

• Statistical Significance: p-values typically < 0.05, adjusted for multiplicity
• Clinical Meaningfulness: Magnitude of effect that has real-world relevance

Even statistically significant findings may not be accepted if the effect size is marginal or inconsistent across subgroups.

4. Conduct Pre-Specified Subgroup and Sensitivity Analyses

To strengthen claims:

• Use forest plots to show consistency across age, gender, region, and baseline disease severity
• Pre-specify responder definitions and use them in analysis plans
• Perform missing data imputation and scenario testing

This evidence helps regulators evaluate robustness and generalizability.

5. Document Claim Support in the Clinical Study Report (CSR)

The CSR should include:

• Detailed description of endpoints used to support each claim
• Statistical methods and p-values
• Safety results that support benefit-risk profile for the claim
• Data visualizations (Kaplan-Meier curves, bar charts, forest plots)

All claims discussed in the product label must have traceability back to the CSR and statistical outputs.

Label Sections Where Claims Appear

In FDA and EMA labeling formats, claims are typically reflected in:

• Section 1: Indications and Usage
• Section 2: Dosage and Administration
• Section 5: Warnings and Precautions
• Section 14: Clinical Studies – detailed evidence supporting claims

EMA SmPC (Summary of Product Characteristics) also contains similar claim structures under “Therapeutic Indications” and “Pharmacodynamic Properties.”

Comparative Claims – A Special Category

Superiority or non-inferiority claims require:

• Head-to-head Phase 3 trial
• Validated comparator approved for the same indication
• Non-inferiority margin pre-approved by regulators

Indirect comparisons (e.g., network meta-analyses) are generally insufficient unless supported by multiple robust sources and discussed during scientific advice meetings.

Quality of Life (QoL) and PRO Claims

PRO-based claims require:

• Use of validated tools (e.g., EQ-5D, SF-36, FACT-G)
• Defined responder thresholds
• Evidence of reliability, sensitivity, and meaningfulness

These claims are typically reflected in the “Clinical Studies” or “Patient Experience” section and require strong support to avoid rejection.

Common Pitfalls to Avoid

• Using exploratory endpoints to support main claims
• Inconsistent definitions of responders across trials or reports
• Failure to account for multiplicity when testing secondary endpoints
• Overstating effect size without statistical proof or real-world support

Case Study: Label Claim Strategy in a Metabolic Disease Trial

A sponsor conducted a 52-week Phase 3 trial for a metabolic disease with two co-primary endpoints: HbA1c reduction and weight loss. They also included a PRO as a secondary endpoint.

• Statistically significant results were achieved for both co-primary endpoints
• Consistency across subgroups and sensitivity analyses confirmed robustness
• The PRO endpoint met MCID criteria using a validated scale

Outcome: The product was approved with claims for glycemic control, weight reduction, and improved patient-reported treatment satisfaction in the U.S. and EU.

Best Practices Summary

• Start with the end in mind: Design trials to support specific claims
• Use validated endpoints: Align with regulatory guidance
• Pre-specify and power: Plan statistical methods early
• Ensure traceability: Link all claims to Phase 3 evidence
• Collaborate across teams: Regulatory, clinical, stats, and commercial must align

Final Thoughts

Label claim justification isn’t just a regulatory formality—it’s the bridge between scientific discovery and real-world market success. Phase 3 data must not only demonstrate efficacy and safety but also support claims that clinicians, payers, and patients can rely on. A strategic approach ensures that every statement on the label is evidence-based, defensible, and impactful.

At ClinicalStudies.in, learning how to justify label claims positions you for strategic roles in regulatory affairs, clinical development, medical writing, and product strategy.